Last week the Supreme Court shielded makers of generic drugs from suit as long as their labels follow the brand-name (BN) counterpart. As a result consumers harmed by inadequate warnings can obtain relief only if they purchase BN drugs. The good news: generics will get cheaper as fear of lawsuits is reduced. The bad news: generic manufacturers will no longer be required to monitor their product’s safety.